Health News   Health Library   Health Topics   Healthy Living   HealthLink
Today's Headlines    Health Alerts    Health News Feature   
Future of Medicine    Health Observances    Product Recalls
Illnesses & Conditions    Drug Guide    FDA Drug Approvals    Complementary Medicine    Medical Tests   
Self-Help Resources    Medline Search
Allergies    Asthma    Back Pain    Cancer    Caregiver    Depression    Diabetes    Digestive Disorders
Heart Disease    Kidney Disease    Men's Health    Parenting    Pregnancy    Senior's Health
Stress    Stroke    Women's Health
Fitness    Nutrition    Mind & Body    Family & Home







Today's Headlines

Health News
Daily articles from HealthDay News: breaking news on health issues, drug approvals and recent discoveries.

Cystic Fibrosis Treatment May Cause Hearing Loss


Ear evaluation urged for youngsters taking common antibacterial medication

THURSDAY, July 2 (HealthDay News) -- A common antibacterial treatment for cystic fibrosis can cause sensorineural hearing loss, finds a new study.

Researchers reviewed the medical records of 50 cystic fibrosis patients treated over a 13-year period at Children's Hospital Boston and found that seven (14 percent) of them suffered from sensorineural hearing loss. Of those seven patients, 43 percent had received more than 10 courses of aminoglycosides intravenously.

Patients who underwent more than five treatments with nasal irrigation of aminoglycosides were also at risk for sensorineural hearing loss, the study found.

Pulmonary and sinonasal infections are common in cystic fibrosis patients. Because of their potency against bacteria, aminoglycosides are often given to cystic fibrosis patients, even though the treatments are known to cause side effects such as hair cell loss, which leads to hearing loss, according to information in a news release from the American Academy of Otolaryngology -- Head and Neck Surgery.

Cystic fibrosis patients should have regular hearing tests that specifically assess sensorineural hearing loss, especially when patients have undergone repeated courses of systemic or intranasal aminoglycoside treatments, the researchers concluded.

The study appears in the July issue of the journal Otolaryngology--Head and Neck Surgery.

More information

The Cystic Fibrosis Foundation has more about cystic fibrosis.

SOURCE: American Academy of Otolaryngology -- Head and Neck Surgery, news release, July 1, 2009
Copyright © 2009 ScoutNews, LLC. All rights reserved.
Health News Provided By:
HealthDay


Powered by Healthvision